Opendata, web and dolomites

Syn2Psy SIGNED

Synaptic Dysfunction in Neuropsychiatric Disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Syn2Psy project word cloud

Explore the words cloud of the Syn2Psy project. It provides you a very rough idea of what is the project "Syn2Psy" about.

structural    clinical    university    suffering    illness    marionet    risk    patients    health    connectivity    therapeutic    disorders    complementary    employment    inform    disability    public    regulate    questions    drive    zeiss    outreach    prospects    signatures    theatre    alleviating    models    diverse    integrate    societal    speaks    mental    eurotrials    drug    synapse    sectors    defects    synaptic    area    excellent    14    basis    scientific    acquired    course    worldwide    stage    neuronal    esrs    syn2psy    contributions    disrupted    implicated    generation    soft    ph    circuits    skills    industrial    coimbra    transferable    flourishing    students    careers    time    burden    clinic    brain    therapies    company    animal    train    academic    lundbeck    functional    genetic    human    hospital    answer    network    convergent    disease    neuropsychiatric    biological    modulate    basic    individual    actions    aetiology    abnormal    underpinning    levels    training    pin    critical    plasticity    expose    combines    trials    child    thriving    neuroimaging    identification   

Project "Syn2Psy" data sheet

The following table provides information about the project.

Coordinator
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO 

Organization address
address: UNIVERSIDADE DE COIMBRA, LARGO DE POMBAL
city: COIMBRA
postcode: 3004 517
website: www.cnbc.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 3˙885˙134 €
 EC max contribution 3˙885˙134 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2023-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO PT (COIMBRA) coordinator 713˙160.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 1˙099˙208.00
3    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 606˙345.00
4    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 606˙345.00
5    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 562˙553.00
6    H. LUNDBECK AS DK (VALBY) participant 297˙522.00
7    CARL ZEISS SMS GMBH DE (JENA) partner 0.00
8    CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E. PT (COIMBRA) partner 0.00
9    Eurotrials Scientific Consultants PT (Lisboa) partner 0.00
10    MARIONET-ASSOCIACAO CULTURAL PT (COIMBRA) partner 0.00
11    PIN - Progresso Infantil PT (Paço de Arcos) partner 0.00

Map

 Project objective

The large public health burden and individual suffering associated with mental disorders speaks to the need to study their biological underpinning. Genetic research, animal models of disease and human neuroimaging studies have provided convergent evidence to common pathways implicated in their aetiology, namely pathways that regulate synapse development and plasticity, which result in abnormal structural and functional connectivity in the brain of neuropsychiatric patients. The time has come to integrate studies across different levels, leading to the identification of signatures of illness associated to specific risk pathways, which can drive the development of novel therapies.

The objective of Syn2Psy is to provide high-level Ph.D. training for 14 early stage researchers (ESRs) to answer three critical questions: 1) What are the synaptic defects at the basis of neuropsychiatric disorders? 2) Which are the neuronal circuits that are disrupted, and may be targets for therapies? 3) How and when can we modulate the course of disease? Syn2Psy combines strong scientific with complementary know-how from the non-academic sector, and network-wide actions on scientific and complementary soft skills, to train a new generation of high achieving ESRs and provide them with the transferable skills necessary for thriving careers in a flourishing area. Industrial partners Lundbeck, Eurotrials and ZEISS provide experience on drug, clinical trials and technology development, the Coimbra University Hospital will expose the students to clinical research, while the clinic for child development PIN and the Marionet theatre company offer training in societal awareness and outreach. The excellent basic scientific knowledge and diverse skills acquired by ESRs will enhance their employment prospects in both the academic and non-academic sectors, and their scientific contributions will inform novel therapeutic approaches for alleviating this leading cause of disability worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN2PSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYN2PSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More